Randomized trial long-term results confirm the benefits of neoadjuvant chemoradiotherapy plus surgery for esophageal cancer

Ten-Year Outcome of Neoadjuvant Chemoradiotherapy Plus Surgery for Esophageal Cancer: The Randomized Controlled CROSS Trial – Journal of Clinical Oncology

Commentaries on Twitter

Out at @ASCO_pubs
🔟yr Outcome of Neoadj #Chemoradiotherapy➕Surgery for #EsophagealCancer

☑️Show OS benefit in locally advanced resectable esophageal or junctional #Cancer who receive preop chemorad🧪☢️ According to CROSS, persists at least🔟years‼️https://t.co/yJSibSveAh pic.twitter.com/UssnzuFiEe

— Gil Morgan, MD (@weoncologists) May 14, 2021

Survival benefit of preoperative chemoradiotherapy for patients with esophageal cancer persists – 10-year outcome of the CROSS trial https://t.co/s02sMVpYhI #esocsm #JCO @ErasmusMC @bmeyck pic.twitter.com/2JwV0iOvoB

— Journal of Clinical Oncology (@JCO_ASCO) May 5, 2021